Health ❯ Healthcare ❯ Obesity

Weight Management

GLP-1 Drugs Mounjaro Medications Dietary Medications Dietary Interventions Weight Loss Medications Clinical Trials Appetite Control Medication Options Semaglutide for Weight Loss Prescription Medications GLP-1 Receptor Agonists Medication Effects Medication Management Hormonal Treatments Tirzepatide Weight-loss Injections Hormonal Imbalance Anti-obesity Injections Weight Loss Treatments Patient Experiences Diabetes Management NHS Rollout Guidelines Fat Jabs Dietary Strategies Anti-Obesity Medications NHS Treatments Patient Support Weight Loss Drugs Semaglutide Weight-loss Medications Belly Fat Reduction GLP-1 Drugs for Obesity Deprescription Strategies Semaglutide Trials Menopause CagriSema Clinical Outcomes Therapeutic Efficacy Diet and Exercise Behavioral Interventions Incretin-based Therapies GLP-1 Agonists Compounded Medications Weight Loss Alternatives Mounjaro for Weight Loss GLP-1/GIP Dual Agonists Drug Treatments Oral Medications Behavioral Programs Wegovy Injections Weight-loss Drugs Obesity-related Conditions Diet and Lifestyle Changes GLP-1 Medications BMI Guidelines Ozempic Semaglutide Effects Weight Regain Weight Loss Programs Medication Efficacy BMI Calculations Slimming Injections Public Health Tirzepatide for Obesity Dietary Supplements BMI Medication Treatment Options GLP-1 Treatment Prescription Guidelines Lifestyle Changes Belly Fat

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

The company released topline, open-label results that await full review.

Novo Nordisk Files FDA Application for Weekly CagriSema Obesity Shot as GLP-1 Competition Intensifies

Lilly’s Triple-Agonist Retatrutide Shows Major Phase 3 Weight Loss as Grey-Market Use Prompts Warning

EMA Panel Backs Higher 7.2 mg Wegovy Dose for Obesity

CHMP Backs Expanded EU Use of Mounjaro for Diabetes in Patients 10+ and Adult Weight Management

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

Stopping GLP-1 Weight-Loss Drugs Before Pregnancy Linked to Higher Gestational Risks, Study Finds

Lancet Analysis: Semaglutide Cuts Major Heart Events Regardless of Weight Loss

Kailera Therapeutics Raises $600 Million to Fund Global Phase 3 of Obesity Drug

Phase 3 Trials Show Greater Weight Loss With 7.2 mg Injection and 25 mg Oral Semaglutide

Cue-Driven Eaters Lose More Weight on GLP-1 Drugs, Japanese Study Finds

Preoperative GLP-1 Agonists Linked to Weight Loss Without Raising Postoperative Risk

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Novo Nordisk’s Amycretin Achieves Up to 24% Weight Loss as It Advances to Phase 3

Bariatric Surgery Surpasses GLP-1 Drugs in Real-World Weight Loss

Real-World GLP-1 Therapy Yields Lower Weight Loss, Spurs Tetra-Receptor Drug Research